Placing patient needs at the center of the combination product development process
Daniel J. Lock, Vectura
Respiratory Drug Delivery 2023 Antibes, France 2–5 May, 2023
- The delivery of orally inhaled drug products (OIDPs) by nebulization is a long-standing mode of administration for the treatment of respiratory disease, with numerous marketed drug-device device combinations administered at home and in controlled clinical settings .
- Unlike typical dry powder inhalers (DPI) and pressurized metered dose inhalers (pMDIs) nebulizer performance is measured in terms of treatment duration. Reducing treatment time is crucially important for all patients, especially for those with high treatment burden disease, such as cystic fibrosis and pulmonary arterial hypertension .
- This study evaluated the aspects of nebulized drug delivery that can be optimized by the formulator and device engineer to ensure OIDPs can be effectively delivered in the shortest possible time, using Vectura’s FOX® vibrating-mesh nebulizer (VMN)
1. Martin AR, Finlay WH; Nebulizers for drug delivery to the lungs, Expert opinion on drug delivery 2015, 12: 889-900
2. Dobler CC, Harb N, Maguire CA, Armour CL, Coleman C; Treatment burden should be included in clinical practice guidelines, BMJ (clinical research ed.) 2018, 363